Novocure — Third Quarter 2026 Earnings Summary

Novocure reported third-quarter 2026 net revenues of $193.4 million, representing a 16% year-over-year increase driven by 19% growth in active patients globally. The company raised its full-year 2026 financial guidance to net revenues between $736 million and $743 million and adjusted EBITDA between $24 million and $34 million. Key operational milestones included the approval of Optune Pax in Japan for locally advanced pancreatic cancer and the achievement of a record 5,260 total active patients on Tumor Treating Fields therapies.